title: Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.
abstract: The present study examined whether reserpine-induced oral dyskinesia is mediated by release of residual endogenous dopamine. Amphetamine produced a dose-dependent change in reserpine-induced oral dyskinesia in which the response was exacerbated by 0.6 mg/kg amphetamine and inhibited by 1 mg/kg. The latter dose also produced stereotypy that may have interfered with expression of reserpine-induced oral dyskinesia. Nigrostriatal 6-hydroxydopamine lesions attenuated expression of reserpine-induced oral dyskinesia. These lesions did not reduce locomotor activity, however, indicating that the attenuation of reserpine-induced oral dyskinesia was not due to a general depressant effect of the lesions on motor behavior. These results suggest that increasing dopamine release by administration of amphetamine exacerbates reserpine-induced oral dyskinesia, whereas decreasing the amount of releasable dopamine in the striatum by 6-hydroxydopamine lesions attenuates reserpine-induced oral dyskinsia. These findings may have implications for understanding tardive dyskinesia and L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia.
authors.affiliation: Department of Psychology, Arizona State University, Tempe 85287-1104, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Neisewander
authors.forename: E
authors.initials: E
authors.lastname: Castañeda
authors.forename: D A
authors.initials: DA
authors.lastname: Davis
authors.forename: H J
authors.initials: HJ
authors.lastname: Elson
authors.forename: A N
authors.initials: AN
authors.lastname: Sussman
mesh_terms: D018663:Adrenergic Agents / Q000494:pharmacology*; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D016627:Oxidopamine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012110:Reserpine / Q000009:adverse effects*; D013239:Stereotyped Behavior / Q000187:drug effects / Q000502:physiology; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology
chemical_list: D018663:Adrenergic Agents; D015259:Dopamine Agents; D012110:Reserpine; D016627:Oxidopamine; D000661:Amphetamine; D004298:Dopamine